Johnson & Johnson to Acquire Ollin Biosciences for $2.2 Billion to Boost Eye Care Pipeline
Key Facts
Johnson & Johnson agreed to acquire Ollin Biosciences for an upfront cash payment of $2.2 billion. Reuters reported that the deal could include additional milestone payments totaling approximately $1.125 billion, with the transaction expected to close before year-end. The acquisition centers on OLN324, a Phase 3 clinical-stage treatment targeting retinal diseases such as wet age-related macular degeneration.
Blackstone Life Sciences will provide $750 million in funding for the development of OLN324 in exchange for future royalties and milestone payments. Johnson & Johnson was trading at $284.38 on November 16, 2026, while Blackstone Inc. closed at $120.19 on November 13, 2026. The deal adds depth to the pharmaceutical pipeline without stretching the balance sheet, as the upfront price represents approximately 0.3% of the company's market capitalization.